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Abstract
In practice, critical care practitioners individualize treatments and goals of care for each patient in light of that
patient’s acute and chronic pathophysiology, as well as their beliefs and values. Yet critical care researchers
routinely measure one endpoint for all patients during randomized clinical trials (RCTs), eschewing any such
individualization. More recent methodology work has explored the possibility that enrollment criteria in RCTs can
be individualized, as can data analysis plans. Here we propose that the specific endpoints of a RCT can be
individualized—that is, different patients within a single RCT might have different secondary endpoints measured. If
done rigorously and objectively, based on pre-randomization data, such individualization of endpoints may improve
the bedside usefulness of information obtained during a RCT, while perhaps also improving the power and
efficiency of any RCT. We discuss the theoretical underpinnings of this proposal in light of related innovations in
RCT design such as sliding dichotomies. We discuss what a full elaboration of such individualization would require,
and outline a pragmatic initial step towards the use of “individualized secondary endpoints” in a large RCT
evaluating optimal enteral nutrition targets in the critically ill.
Background
Selecting endpoints that are both measurable and im-
portant to patients for randomized clinical trials (RCTs)
during critical illness is challenging but inadequately
studied. Trial designers, reviewers, and funders seem to
prefer mortality as the summary endpoint [1, 2]. Yet
there is evidence that patients with serious illnesses or
injuries believe their physical function and cognitive
capacity are as important, or even more important, to
their decision-making [3], and these topics are
frequently discussed in family meetings [4].
We suggest that the conventional RCT practice of
measuring exactly the same endpoint for all study partic-
ipants can be improved upon. (For an overview, see
Fig. 1) We suggest that our trial designs can and should
better reflect our clinical approach, which is to
individualize goals of care to what is both achievable and
desirable for each patient. We further suggest that such
individualization of the endpoints of trials might be
possible, might be feasible, and might be done rigorously
in a way that preserves the unique ability of RCTs to
discover the truth. More importantly, individualization
of endpoints might even enhance the power of RCTs to
detect meaningful effects. These conjectures are un-
proven, but we offer them for consideration in light of
recent innovations in RCT design.
A conceptual goal: clinicians and patients picking
their endpoints together as part of goals of care
In an ideal world, clinical teams and patients (or their
surrogate decision-makers) come together in a process
of shared decision-making before initiating a treatment
regimen. Part of that shared decision-making is under-
standing the outcomes that are clinically feasible and
which are most desirable to the patient, in light of the
patient’s values and goals [5]. We believe this concept of
feasible and desirable outcomes according to individual
circumstances could animate RCT endpoint ascertainment.
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We therefore propose that an appealing endpoint for an
RCT is to ask: “Did random assignment to this intervention
when compared with control help the patient reach the
achievable outcome that they considered desirable when
commencing the treatment?” Differences in rates of such
desirable outcomes, in addition to mortality, might then
provide a more nuanced understanding of an intervention’s
worth—and increase the appeal of RCT participation for
patients and families.
Past work on individualizing RCT endpoints:
building on concepts developed in neuro-critical
care RCTs
In neurologic critical care, RCT methodology frequently
includes measurement of participants’ outcomes on a
categorical scale, such as the Glasgow Outcomes
Scale—Extended (GOS-E), with an undesirable outcome
defined as an outcome worse than some predefined level
of disability [6]. However, several studies have recently
also utilized a so-called “sliding dichotomy” to quantify
outcomes [7, 8]. In brief, a sliding dichotomy works as
follows. Based on the size of the neurologic injury on a
computerized tomogram (CT) scan performed prior to
randomization, patients are stratified according to
potential disability. Patients with a larger volume of
damage and with features consistent with a poorer prog-
nosis will have a “desirable” outcome categorized as any-
thing better than moderate disability, whereas patients
with a smaller volume of damage and features consistent
with a better prognosis instead have a “desirable” out-
come categorized as complete functional recovery. This
“sliding dichotomy” approach allows the effect of the
intervention to be measured in the range relevant to the
severity of the presenting problem.
Accordingly, sliding dichotomies might simultaneously
increase the power of the trial and come closer to pro-
viding the truth about the benefits (or harm) of an inter-
vention that is relevant to both clinicians and patients.
(There are limitations, however, as discussed below.) In
particular, this approach allows a single RCT to enroll
patients across a spectrum of disease or injury, since the
sliding dichotomy individualizes the endpoint to the
severity of the presenting problem. Given that individu-
alizing endpoints may better illuminate the truth of an
intervention administered to participants with a single
organ (neurological) problem, we propose that the
advantages could be even greater when implementing
this methodology in critical care RCTs enrolling a more
heterogeneous cohort of patients.
The “sliding dichotomy” methodology illustrates prin-
ciples relevant to our proposal to individualize trial
endpoints. The sliding dichotomy emphasizes that a
desirable outcome should be considered in the context
of the specific patient and the circumstances related to
their presentation. It also reminds us that the
individualization must be based exclusively on character-
istics of the patients that are measured prior to
randomization [9]. This is because inclusion of post-
randomization information (which could be influenced
by the intervention under study) risks bias and thereby
incorrect inferences—and will lead to worse clinical
decisions based on false understanding [9].
We believe that there are limitations to sliding
dichotomies, however, particularly when enrolling partic-
ipants with a variety of pathologies. First, the focus has
been primarily on the characteristics of the presenting
insult to individualize endpoints, rather than considering
the vastly different lives the participants lived prior to
hospitalization. Second, it is assumed feasible to measure
outcomes for all participants using a single instrument
Fig. 1 How variation in patients’ lives, critical illness, and care
interact to produce assessable outcomes. RCT randomized
clinical trial
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as the endpoint of the RCT, and that this instrument is
uniformly responsive and reliable across the entire range
of patients. We conjecture that both of these limitations
can be improved upon.
Experience with sliding dichotomies emphasizes that
some conservatism is appropriate before changing RCT
endpoints, particularly primary endpoints. Despite initial
promise, data suggest that sliding dichotomies often do
not improve the power of RCTs [10, 11]. This experience
emphasizes that, during development, potential innova-
tions regarding endpoints should be limited to second-
ary, rather than primary, endpoints.
Individualization of RCT endpoints should be consid-
ered in light of the recent burst of activity regarding
ways to build on the unique power of RCTs to provide
causal evidence to inform individual patient care. This is
complementary to efforts to improve RCT enrollment
criteria [12] by considering initial physiologic response
to therapy [13], or specific genetic subtypes or
biomarkers [14–16]. It is similarly complementary to
proposals to examine RCT primary endpoints after
stratification for baseline risk of death, not just
intervention-specific physiology [17–21]. The unifying
thread is recognition that RCTs are incredibly powerful
in measuring population-average effects. This work
hopes that RCTs may be made even more powerful for
informing individual patient decision-making without
returning to an era of anecdote-based medicine.
An ideal approach to individualization of
endpoints without prior contact
The conceptual goal described is often pragmatically
impossible. One simple but perhaps ineluctable
challenge is that ICU clinicians rarely meet their pa-
tient before the onset of critical illness. There is
rarely a time when there is knowledge of what the
actual critical illness is and the patient (or surrogate
decision-maker) has the time and capacity to consider its
implication without the stress of crisis. While there are
exceptions—such as before high-risk surgery [22]—what
constitutes a desirable outcome for each individual patient
during clinical care is usually co-constructed by an itera-
tive process to facilitate gathering of relevant information
and building of trust.
The inability to have pre-illness discussions does not
mean individualization is impossible. We routinely make
ethical and individualized treatment decisions for most
patients using the principle of substituted judgment and
the practical sources of information about that judgment
from families, loved ones, and the way the patient lived
his or her life prior to critical illness.
However, for this approach to be included within a
RCT, the process would need to be formalized and (as
discussed) be completed using only information that
cannot be affected by post-randomization factors. We
believe that a structured, rapid values clarification
instrument could be developed to obtain relevant infor-
mation from surrogate decision-makers, family, and/or
friends. A prognosis could be elicited from the care team
and a standard social and medical history also provides
information about pre-illness disability. Ideally, values
clarification and prognosis could be combined algo-
rithmically to indicate the feasible outcomes and,
individualized for this patient, their desirability. The
endpoint for the trial would then be based on this
individualized ranking of desirability of those out-
comes. For each individual, the particular endpoints
used would focus on the types of outcomes most
likely and relevant to that patient.
In practice, the tools to conduct such a process rapidly
and without bias have not been built. But this does not
mean that they could not be. The work outlined has simi-
larities to the methodology used for the development of
health-related quality of life (HRQoL) scales [23]. HRQoL
developers first established a list of questions that they
believed summarized the main components of quality of
life. Various answers to these questions were then com-
bined to develop a set of all possible combinations—this
was then taken as the set of all possible disability states.
Population surveys were used to rank these disability states.
Those average rankings across the population were then
scaled to create the HRQoL scale [23]. What we propose is
conceptually similar, but we also want to reflect outcome
rankings according to each individual rather than simply
imposing the population-average rankings on everyone,
while also addressing certain practical constraints regarding
how many questions can be asked (see below).
A first approximation for RCTs in the critically ill:
the TARGET approach to individualization
We believe that certain broad generalizations can be made
for participant categorization within a RCTand remain true
to the overarching objective of individualizing endpoints.
As an initial step we propose the following generalizations:
 For employed, working-age people, a desirable and
measurable outcome is to get back to a comparable
level of employment.
 For people who primarily provide unpaid care to
others, a desirable and measurable outcome is to get
back to being able to provide a comparable level of
caregiving.
 For high-functioning retired people, a desirable and
measurable outcome is for them to be able to con-
tinue participating in their full range of social roles.
 For people already with some degree of disability, a
desirable and measurable outcome is to prevent
worsening of that disability.
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These generalizations are clearly value-laden, and we
acknowledge this. They typically incorporate a societal
perspective that seeks to return people to productive
roles whenever possible; in our increasingly diverse soci-
eties, this may not always be a shared goal. While there
are certainly anecdotal counter-examples, we believe the
following statements offer at least as much truth as the
status quo for these heterogeneous groups of patients:
 For employed, working-age people, the desirable and
measurable outcome is to be alive 90 days after
admission.
 For people who primarily provide unpaid care to
others, the desirable and measurable outcome is to
be alive 90 days after admission.
 For high-functioning retired people, the desirable
and measurable outcome is for them to be alive 90
days after admission.
 For people already with some degree of disability,
the desirable and measurable outcome is to be alive
90 days after admission.
We have used these generalizations to design a pro-
gram that may provide greater individualization of
secondary endpoints for The Augmented versus Routine
approach to Giving Energy Trial (TARGET) in critically
ill patients. This multicenter, prospective, parallel group,
double-blind RCT, endorsed by the Australian New
Zealand Intensive Care Society Clinical Trials Group
(ANZICS-CTG), will determine whether augmentation
of calorie delivery using energy-dense enteral nutrition
in mechanically ventilated patients improves 90-day
survival when compared with routine care (Clinical-
Trials.gov NCT02306746). The sample size of 4000 was
based on data derived from the feasibility study [24] and
will provide 80 % power to detect an absolute difference
in the primary outcome of about 4 percentage points
(depending on baseline mortality) in 90-day mortality,
with functional outcomes as secondary endpoints.
To uncover the truth in relation to this secondary end-
point (functional outcomes), our proposal requires end-
point assessments that are appropriate for the full range
of potential ICU patients. Because the intervention in
TARGET examines a ubiquitous treatment decision, en-
teral feeding in the critically ill, even relatively modest
individual-level effects are likely to have large total
population-level effects [1]. Detecting such effects there-
fore requires a responsive secondary endpoint.
Within TARGET we first propose an approach to sec-
ondary outcome ascertainment that includes only pre-
randomization information and will assign patients to one
of eight mutually exclusive and exhaustive categories
(Table 1, and described below). All patients will then have
an endpoint measured according to their specific category.
This design sought to balance several desiderata. First, we
wanted to pick categories for which we believed there was a
plausible consensus about what might constitute a desirable
outcome. Second, we wanted categories that aligned with
goals of care for which there were existing, validated, and
reliable measurement tools. Third, we wanted enough
categories that patients within each category felt similar,
but not so many as to excessively fracture the cohort
thereby limiting interpretation of data via either summary
or inferential statistical analyses—this in particular requires
some understanding of the expected distribution of patients
within the final enrolled population, for which pilot work
may be very valuable. To achieve the latter goal we limited
the number of categories to eight.
Specific TARGET pairings of category and
endpoints
We began this process by pairing each of the eight
categories with a proposed endpoint. It was important
that longitudinal data regarding the proposed endpoint
would be obtainable within a large pragmatic RCT and,
if the intervention affects the outcomes, that the out-
comes would also be important to patients, their care-
givers, and/or the community. Initial categorization was
based on age, with further divisions as shown in Table 1.
For example, for patients aged less than 65 years and
employed before critical illness, we ask how much they
work. For patients who were retired and living inde-
pendently, we ask to what extent they are able to partici-
pate in the social activities of retirement [25]. For
patients who were already in a nursing home, we instead
ask whether they were independent in their activities of
daily living (ADLs and IADLs) [26, 27]. Since baseline
characteristics within the groups should be balanced (or
at least differences allocated randomly), we can be rela-
tively confident that any differences in secondary end-
points measured should represent the truth and be due
to the intervention. If this individualization approach
proves fruitful, one might consider eventually stratified
randomization.
Approach to analyzing individualized endpoint
data
The simplest approach to analyzing these secondary
endpoint data is to consider each category of patients
separately. In this sense, one approaches the secondary
endpoints as if one were running eight RCTs in parallel.
Since the categories are, we believe, both mutually exclu-
sive and exhaustive, all such patients fit in one – and
only one – category. Such subdivided secondary analyses
are often used for primary endpoint of RCTs, such as
when subgroup analyses are carried out for pre-stratified
categories (e.g. age, comorbidity, or baseline risk of
death groups).
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Initially there may be concerns regarding the limi-
tation of such stratified analyses in that, with the
addition of each category, the subsequent reduction
in sample size will both strongly bias a RCT towards
the null and reduce our confidence in the result. It
is true that, all else being equal, a larger sample size
increases the power of a RCT. But sample size is
not the only consideration (and may not even be the








In this formula, confidence is equivalent to power.
Confidence falls as the sample size falls, but not linearly.
However, confidence grows as the signal increases and
noise decreases. We hypothesize that individualization
of endpoints offers a novel approach to improve the
ratio of signal to noise via:
– increased responsiveness (reduced noise). In order
to achieve reasonable response and completion
rates, most studies have used instruments that are
relatively brief. The fewer questions that are asked,
the less detail that can be collected. With fewer
gradations in response available, heterogeneous
patients are lumped together. By targeting
measurement to the range of outcomes most likely
to have been affected by the intervention,
individualization can increase responsiveness by
utilizing the time and effort required when obtaining
follow-up information to measure only highly
relevant variables in detail. Consider, for example,
examining the broad domain of “disability”. For a fit
young employed person, we believe it is important
to evaluate the effect of any intervention on their
employment and exercise tolerance; in contrast, a
nursing home resident would already have
permanently left the labor force, but might be at risk
of losing independence with a reduction in ADLs and
IADLs. Both scenarios have consequences not only
for the patient but also for society. Without
individualization, we need to ask both participants
the same set of questions or perform the same tests.
This need to cover such a broad range results in a
trade-off because, assuming finite follow-up
resources in any large pragmatic RCT, we cannot
determine outcomes in granular detail about
employment, exercise tolerance, ADLs, and IADLs
for all study participants.
– naturally continuous measures (reduced noise).
One reason for the preference for mortality over
certain composite measure in past RCTs may be the
greater comprehensibility of mortality. However,
binary endpoints such as mortality substantially
reduce power relative to continuous variables [29].
Individualized endpoints such as hours worked or
IADLs are frequently either continuous variables or
discrete variables with more than two categories,
and yet retain the intuitive comprehensibility of alive
or dead 90 days later.
Table 1 TARGET initial proposed categorization and outcome scale
Category Endpoint Measure
Younger than 65 years of age
Paid employment
(or unemployed but looking for work)
Hours spent
working
Official Australian Labour Force Survey Questions on hours and nature of employment
Unpaid caregiving
(including parenting of children)
Hours providing
care
Aging, Demographics, and Memory Study (ADAMS) Caregiving Provision Questions [34]
Studying Hours studying
or working
Official Australian Labour Force Survey Questions on hours and nature of employment
including hours spent studying
Chronic disability Disability Living at Home or In Supportive Accommodation, and Independence in Activities of
Daily Living (ADLs) [26] and Instrumental Activities of Daily Living (IADLs) [27]
Environmentally disadvantaged Life satisfaction OECD Life Satisfaction Measure [35]
Aged 65 years and older
Living fully independently Participation National Health & Aging Trends Study (NHATS) “Participation in Activities” Measures [25]
Living independently with essential
supports
Disability Living at Home or In Supportive Accommodation, and Independence in Activities of
Daily Living (ADLs) [26] and Instrumental ADLs (IADLs) [27]
Living in supportive accommodation Disability Independence in Activities of Daily Living (ADLs) [26] and Instrumental Activities of Daily
Living (IADLs) [27]
TARGET’s proposed primary endpoint is 90-day mortality. All patients will complete an eq-5d-5l as part of their secondary endpoint assessment at day 180. In
addition, the presented category-specific secondary endpoints will be assessed at day 180 after randomization
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– better alignment with benefits of therapy
(increased signal). Interventions that are not
intended directly to prevent death are frequently
evaluated. Instead, prevention or delay of death is
one of many hypothesized downstream benefits of
the intervention. If individualized endpoints are
more closely aligned with the mechanism for the
intervention to benefit a defined subgroup of
patients, then the effect size (or signal) on those
individualized endpoints will be much greater than
the effect size on some unified endpoint, such as
mortality. A larger effect size requires a smaller
sample to detect and provides greater confidence in
the results.
Asking individualized measurement scales and analyz-
ing them separately is a first step to individualization. A
more sophisticated approach—albeit one that will
require additional development—would be to develop a
set of response scales that can be harmonized. That is,
for each category or scale, the best feasible outcome is
scored a 1, and the worst feasible outcome scored a 0.
Intermediate outcomes would be arrayed between 0 and
1 in an informative way. If this was done comparably
across a number of different categories, we could calcu-
late an “individualized feasible outcome” score that
could be compared between categories of patients, even
though the measures used to obtain the individualized
feasible outcome score would vary.
Done thoughtfully—and with sufficiently precise
information based on pre-randomization characteris-
tics—such comparable scales might limit floor and ceil-
ing effects. In brief, floor and ceiling effects are when
the range of the score does not reflect the range of
possible actions, and so many participants are clumped
at the lowest (floor) or highest (ceiling) score [30]. This
clumping leads to loss of information. At the most basic
level, when using a binary variable such as mortality, we
dichotomize the entire continuum of health into “alive
at 90 days” and so all survivors are considered similar
and allocated the ceiling score regardless of disability.
Moreover, even when we try to attenuate floor and
ceiling effects we are limited, when using current meth-
odologies, by heterogeneity. For example, if we try and
obtain a more nuanced understanding of the effect of an
intervention on function with the use of IADLs, many
participants may have considerably impaired exercise
tolerance but because of pre-existing greater capacity
(i.e., noise) they are still able to complete IADLs and so
any signal is not detected because these participants are
clumped at the ceiling score—while all deaths will
record the floor score. We suggest that individualization
of outcomes provides at least a partial solution to the
phenomenon of floor and ceiling scoring of outcomes.
Possible objections/limitations
There are a number of reasonable potential objections
to our proposed strategy. One might question whether
the increase in measurement responsiveness and better
alignment with benefits of therapy will actually yield
adequate improvements in power. One might also
question whether the technical complexities of assessing
both pre-randomization variables and individualized
endpoints can be managed by always busy study
personnel. Ultimately, these are empirical questions, not
ones that can be adjudicated on first principles. We are
conducting an initial multicenter cohort to test the reli-
ability of rapid, early classification into the eight categor-
ies we proposed prior to commencing TARGET
(ACTRN12615000942550). This study will compare ini-
tial classification by research coordinators with a gold
standard of later classification of patients once they are
no longer critically ill. Advances in study management
databases—particularly the move from paper records to
electronic data entry—make the matching of various
endpoints to individual patients more feasible than in
the past.
Regardless of the limitations of this initial proposal, we
believe that the current approach to endpoints misses
valuable information from patients, and alternative
approaches to RCT endpoints could bring about effi-
ciencies. Accordingly, attempts to conceive and evaluate
novel approaches are not only desirable but are abso-
lutely essential to improving knowledge and care for
patients. However, such urgency should not lead to pre-
mature adoption of our—or any—proposal as the
primary outcome of any large RCT.
One might question whether current HRQoL scales do
not already provide a precise estimate of outcome indi-
vidualized to each participant. There are two senses in
which they do not. The first is that existing HRQoL
scales use a population-average ranking of various health
states without any effort to individualize them. The
second is (as discussed) that an inherent limitation of
any large pragmatic RCT is the constraint on time and
effort for both participants and researchers such that
depth is traded off for breadth of information. There are
often seemingly disparate outcomes that are lumped to-
gether by these pragmatic limitations in existing HRQoL
instruments, as Lim et al. have shown [31].
Alternative approaches
While we propose categorization to achieve
individualization of endpoints, it is possible, with the
rapid advancement of technology, that our approach
could be superseded prior even to its first use [32].
For example, in computer-adaptive testing, the par-
ticular survey items that are subsequently asked are
dependent on answers to prior questions. For
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example, an initial question might be “Can you walk
one flight of stairs?” If the patient answers “yes”, then
subsequent questions establish how many flights of
stairs or what distance on the flat (in quanta such as
number of kilometers). In contrast, if the initial
answer is “no”, then subsequent questions focus on
whether the patient can walk smaller quanta, such as
across the room, or is bedbound. By asking the most
relevant next question in each case, respondent bur-
den can be dramatically reduced. Such scales require
certain assumptions—particularly regarding there
being only one dimension along which all outcomes
can be uniquely ordered across patients. But if such
adaptive testing was to fully mature, it might offer the
same efficiency benefits as individualization with
harmonized scales. We would welcome this develop-
ment, but it has not yet occurred.
Finally, another alternative approach might simply be
to ask patients: “Are you doing as well as you were
before you got sick?” If patients were reliable and
responsive informants on this topic, this might be the
best possible individualized endpoint. However, there is
reason to fear patients are not reliable informants: crit-
ical illness may change their sense of how bad things
can really be; and gratitude to simply have survived may
change patients’ assessment [33].
Conclusion
Current best practice is to measure the same endpoints,
both primary and secondary, for all study participants.
This one-size-fits-all approach to endpoints for RCTs
offers the advantage of simplicity and transparency. But
to achieve these virtues, a single unifying endpoint is
likely to provide a coarse understanding as to the effect
of the intervention; may miss valuable information; and
creates an artificial distinction between how critical care
clinicians practice and how critical care research is
performed. Because research should complement and
inform practice, we propose that RCTs align method-
ology closer to practice and consider individualization of
endpoints. This approach may reduce sample size under
some analysis plans. However, due to the subsequent
increased signal of effect and reduced noise within the
study, we believe that our proposed approach may have
the capacity to increase power and our confidence in the
results from RCTs. It is essential, now, that this proposal
is tested empirically as a secondary endpoint in several
trials before being adopted as a primary endpoint for
any RCT.
Key messages
 The current approach to endpoints in critical care
RCTs is to measure a single endpoint, frequently
mortality, but such an approach may provide only a
coarse understanding of the effects of the treatment
under study.
 We propose a novel approach, the “individualization
of endpoints”, that if performed in a rigorous
manner could increase our capacity to determine
more nuanced effects of an intervention.
 Individualization of endpoints will reduce the
sample population for each endpoint. However, this
approach may actually result in increased power
within an RCT and provide confidence in the results
by increasing the signal (treatment effect) and
reducing noise.
 Given the current state of knowledge, such
individualization should only be used for secondary
endpoints of RCTs. While it may eventually prove
useful for primary endpoints, the benefits of
individualization are unproven.
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